Pharmaceutical and biotechnology companies
The goal of cooperation with FNUSA-ICRC is the development of new pharmaceuticals, especially in the field of neurology (e.g., Alzheimer's disease, multiple sclerosis, stroke, etc.) and cardiovascular disease (e.g. coronary heart disease, etc.).
- Abbott Laboratories
Abbott Laboratories, Ltd., is a global pharmaceutical company engaged in the development and research of pharmaceuticals, technologies, and ways of protecting health. Abbott’s extensive product portfolio represents a broad range of care, from nutritional products and laboratory diagnostics through medical devices to pharmaceuticals. The company was founded in 1888 in the USA. Currently, its sales, production, distribution, research, and development facilities are located around the world. The aim of its more than 72,000 employees has been "to transform science into care," which has had a direct impact on the quality of services provided. The Czech subsidiary of the company was founded in 1997. In 2005, it was awarded with Class A certification, which is the highest internationally recognized evaluation standard of management processes.
Cooperation with FNUSA-ICRCCooperation between FNUSA-ICRC and Abbott Laboratories, Ltd., focuses primarily on the development of new pharmaceuticals and medical devices in the form of research and clinical studies.
- AstraZeneca Czech Republic
AstraZeneca is a leading global pharmaceutical company. It was created by the merger of the Swedish concern Astra AB and the British company Zeneca Group plc in 1999. It focuses on research and development of human pharmaceuticals in all fields of medicine. The main activity of the company is its own research programs, focusing on gastroenterology, anesthesiology, cardiovascular diseases, oncology, CNS diseases, infectious diseases, respiratory diseases, and diseases of the joints and bones.
Cooperation with FNUSA-ICRCThe present cooperation between AstraZeneca and FNUSA-ICRC is based on a number of completed research and clinical studies. Future cooperation will focus especially on clinical trials, with the goal of collecting new relevant data about the efficacy and safety of newly-developed pharmaceuticals.
- Biotechnology Research and Information Network
Biotechnology Research and Information Network (BRAIN) is a company engaged in exploring and developing new natural ingredients and special enzymes for its partners and customers in the chemical, pharmaceutical, food-processing, and cosmetics industries. The company was founded in 1993, and it has established more than 60 strategic partnerships with major international companies.
Cooperation with FNUSA-ICRCWithin the ICRC project, BRAIN will contribute to the development of active tests and will allow access to its development platforms.
The biotechnology firm Enantis, Ltd., established in 2006, provides consulting and development services in enzyme technology and protein engineering for biomedical, environmental, agrochemical, and military-defense purposes. The company has been working closely with the Loschmidt Laboratories of Masaryk University in Brno.
Cooperation with FNUSA-ICRCThe expected outcomes of the cooperation between Enantis, Ltd., and FNUSA-ICRC will be new protein materials and technology.
GeneProof plc is a Czech biotechnology company engaged in the development and manufacture of molecular in-vitro diagnostics. The company develops, manufactures, and supplies technologically advanced, high-quality, user-friendly, and affordable products for routine laboratory diagnostics in the field of clinical microbiology, clinical genetics, and pharmacogenetics. GeneProof plc was founded in 2005 by the research and development firm Genex CZ, Ltd., as a tool for the commercialization of research results and the development of the parent company. The predominant products of the company are PCR kits for detecting and analyzing nucleic acids. The company has cooperated in the development of universities and academic institutions and extensively uses subsidy programs from national ministries and the EU.
Cooperation with FNUSA-ICRCCooperation between GeneProof and FNUSA-ICRC is focused especially on applied research and development of diagnostic medical devices (in vitro diagnostics), modern vaccinology preparations (epitope vaccine), and cell therapies (mesenchymal stem cells).
- LentiKat´s plc
LentiKat's plc was founded in 2006 and builds on more than six years of activity by the MEGA company in the area of Lentikats Biotechnology applications. Lentikats is a revolutionary biotechnology that enables the immobilization of free enzymes or cells into a solid medium of polyvinyl alcohol (PVA). PVA (hydrogel) has excellent physical and mechanical properties that provide long-term mechanical stability. It is biologically un-degradable and non-toxic. Lentikats Biotechnology is a simple and inexpensive preparation of robust biocatalysts based on the Lentikats Biocatalyst, which can be used in many industries. The production of this biocatalyst eliminates many costly processes which were unavoidable in the production of previous industrial biocatalysts. Lentikats Biotechnology provides the possibility of both immobilizing enzymes used in biotransformations (thus saving equipment), and replacing the existing cross-linked enzyme aggregates or enzymes immobilized on solid carriers.
Cooperation with FNUSA-ICRCThe goal of cooperation between LentiKat’s and FNUSA-ICRC will be to make advances in the development of new biotechnology processes and clinical evaluation of substances in the biotechnology field.
Pfizer, Ltd., was founded in 1993 and is a member of the Pfizer group, the world's largest pharmaceutical company. Pfizer develops, manufactures, and markets leading prescription pharmaceuticals for human and veterinary use, as well as many other world-renowned consumer products. In addition to the sale of pharmaceuticals, Pfizer, Ltd., is also engaged in educating professionals and is involved in clinical trials testing the medicines in cooperation with hospitals. The main categories of pharmaceuticals that Pfizer, Ltd., is focused on in the Czech Republic include pharmaceuticals for cardiovascular medicine, cholesterol-lowering pharmaceuticals, pharmaceuticals for central nervous system disorders, antibiotics, and pharmaceuticals for erectile dysfunction.
Cooperation with FNUSA-ICRCCooperation between Pfizer, Ltd., and FNUSA-ICRC will take place mainly in clinical trials of new pharmaceuticals.
Sanofi-aventis is a global diversified healthcare company that focuses on patient needs. It is a leading pharmaceutical company in Europe and emerging markets, and the fourth largest in the world. Sanofi-aventis employs over 100,000 people worldwide. The company goal is primarily to come up with new solutions for health care. A significant part of this activity is in the development of new pharmaceuticals, especially for central nervous system disorders such as multiple sclerosis and Alzheimer's disease, for the field of oncology, and for metabolic diseases, with an emphasis on diabetes, cardio-vascular disease, and more. In 2009, Sanofi-aventis became the owner of 100% of the shares in the Czech company Zentiva. Sanofi-aventis focuses on areas with potential for future growth, including generic and non-prescription pharmaceuticals. Zentiva is a leading manufacturer of high quality modern generic products at affordable prices in markets in Central and Eastern Europe. Sanofi-aventis established a platform at the Zentiva headquarters in Prague for generic pharmaceuticals for the group for the European region. Pharmaceuticals and non-prescription pharmaceuticals are sold under the brand name of Zentiva, a member of Sanofi-aventis.
Cooperation with FNUSA-ICRCCooperation is based on many years of successful cooperation in research and development, together representing approximately sixteen clinical studies completed during the past five years, and including projects in the fields of neuroscience (e.g. multiple sclerosis) and cardiovascular disease.
- Schering-Plough Ltd., part of Merck & Co, Inc.
Schering-Plough, Ltd., part of Merck & Co., seeks to promote health worldwide. It operates in more than 140 countries, bringing its customers innovative solutions in the field of health care through pharmaceuticals, vaccines, biological treatments, non-prescription drugs, and veterinary pharmaceuticals. Through a variety of programs it fulfils its commitments to increase the availability of health care and to provide its products to the people who need them.
Cooperation with FNUSA-ICRCThe goal of cooperation between Schering-Plough, Ltd., part of Merck & Co. and FNUSA-ICRC will be the research of new medicines suitable for registration and introduction into everyday use.
Contract research organizations (CRO)
Contract research organizations are primarily concerned with the conduct of clinical trials, testing the efficacy and safety of newly-developed pharmaceuticals and medical devices. FNUSA-ICRC is a very important center with a long history of clinical testing of modern technologies and these activities will be further developed in the future in collaboration with leading CROs.
- ICON Clinical Research
ICON Clinical Research, Ltd., is a part of the global company ICON, which is the 4th largest global provider of research and development of drugs for the pharmaceutical and biotech industries. ICON focuses on the support of clinical trials, providing services such as management of clinical research phases 1 through 4, the preparation of clinical trials, and other services in the area of testing and drug development. The ICON Group was founded in 1990, and has grown from the original 5 employees into an international team of more than 7,100 employees in 38 countries.
Cooperation with FNUSA-ICRCICON Clinical Research, Ltd., has already cooperated with FNUSA-ICRC on several programs and clinical trials, particularly in the field of cardiovascular diseases. The future cooperation will also be directed to this area.
- PPD Czech Republic
PPD is a leading global contract research organization with 25 years of activity in the field of discovery, development, and introduction of pharmaceuticals to the market. Its clients and partners include pharmaceutical and biotechnology companies, manufacturers of medical devices, and academic and government organizations. With offices in 44 countries and more than 11,000 employees, PPD uses new technologies and experience in various indication areas and focuses on maintaining quality. Through this, it helps its clients accelerate the development of safe and effective medicines and maximize the return on their investment in research and drug development. PPD Czech Republic is focused on clinical trials of all indications, particularly in phases II and III.
Cooperation with FNUSA-ICRCThe key area of cooperation between PPD Czech Republic, Ltd., and FNUSA-ICRC will be newly-developed medicines, including the registration and testing of efficacy and safety.
Manufacturers of medical technologies
The area of medical technology encompasses both medical devices where the emphasis is focused on the development of new technologies for neurology and cardiology, and the development and testing of “electronic health care” (e-health), which is focused on the application of modern information and communication technologies for the prevention, early diagnosis, and cure of diseases.
- Association of Manufacturers and Suppliers of Medical Devices
The Association of Manufacturers and Suppliers of Medical Devices is a professional and vocational association of companies whose main activity is coordinating and creating favorable conditions for the growth of the medical devices branch. The Association was established in 1992 and currently has 96 companies, mainly Czech and Slovak, providing services to the healthcare sector and collectively employing approximately 12,600 people. The products of the member companies are of both high technological level and quality.
Cooperation with FNUSA-ICRCThe association has been cooperating with FNUSA-ICRC for many years. During this time, it has cooperated on many important projects and in key meetings associated with the ICRC project. Since the association includes manufacturers developing a wide range of medical technologies, future cooperation will cover virtually all research areas of FNUSA-ICRC.
BioVendor Laboratory Medicine plc is a leading manufacturer and supplier of medical equipment and products for clinical research in the fields of immunology and immunochemistry, biochemistry, hematology, microbiology, virology, and serology. In the Czech Republic, the company represents many major international companies in the field of in vitro diagnostics.
Cooperation with FNUSA-ICRCCooperation between BioVendor Laboratory Medicine plc and FNUSA-ICRC is planned particularly in the development and testing of new products of the company. Given the wide range of BioVendor products, cooperation is expected in almost all FNUSA-ICRC research programs. The development of new diagnostic markers of cardiovascular physiology and metabolic syndrome obesitology will be a particular focus.
Cardion, Ltd., is engaged in the development, manufacture, and sale of implantable medical devices for cardiology, cardiac surgery, neurology, and neurosurgery, and the instrumentation technologies for these and other fields. On the Czech market, the company represents a number of renowned foreign manufacturers of medical devices. Cardion, Ltd., was founded in 1994 as the exclusive representative of St. Jude Medical for the Czech Republic and became a major domestic supplier of medical equipment for cardiology, cardiac surgery, neurology, and other fields. It collaborates with leading international manufacturers of medical devices. The company's customers are mainly specialized centers in the Czech Republic, to which the company offers products from leading manufacturers worldwide and facilitates access to the latest medical technology.
Cooperation with FNUSA-ICRCOne of the results of the recent cooperation between Cardion, Ltd., and FNUSA-ICRC was the delivery of new technologies for the ICRC-CARS animal laboratory of St. Anne’s University Hospital in Brno. Further cooperation will focus in particular on the areas of electrophysiology, interventional cardiology, coronary stents, and the development of hemodynamic monitoring.
The company ELLA-CS, Ltd., founded in 1991 and based in Hradec Kralove, is a purely Czech company employing approximately 90 employees. The main activity of the company is the manufacture of stents, stentgrafts, and extractors for tubular body organs, including arteries and other vessels. The products are destined mainly for foreign markets. The company has three locations, including its own production plant, laboratories, and engineering facilities for the manufacture of machinery, tools, and products. The company continuously works with domestic and foreign physicians to design and develop new products. In development, the company places great emphasis on new types of advanced materials and technologies, which in turn are applied in production.
Cooperation with FNUSA-ICRCCooperation lies primarily in the preparation and execution of studies, using the methods and products of the company, in the field of MIS and NOTES: 1 cooperation in preparing the design of clinical studies and documentation, 2 identification of experts from among the ICRC partners (from both human and veterinary medicine) and definition of their roles, 3 assistance in managing the conduct of studies/trials and cooperation in the evaluation of results, 4 cooperation in preparing the publication of study results.
The ENJOY Company, Ltd., has long been committed to the research and development of non-standard products and technological processes, such as the development and production of electronic switches operated by alternating magnetic fields, the development and practical application of anticorrosion protection technology for ceramic and metal surfaces, the development of special hardware and software products, etc. The company was founded in 1992. Currently, it is focused on research in natural sciences and engineering, especially on research and development of equipment for the generation of planar and laser-pulsed magnetic fields for therapeutic purposes. The results of the research are utilized in constructions of special therapeutic and cosmetic devices.
Cooperation with FNUSA-ICRCThe main area of cooperation between the company and FNUSA-ICRC will be preclinical and clinical testing of ENJOY products, particularly in the development of advanced diagnostic and therapeutic methods for cardiac electrophysiology and pacing and the development of new imaging methods and technologies for the brain and cerebrovascular system.
- IBM Czech Republic
IBM is the leading company in IT services and consultancy, with a more than eighty-year tradition of innovation that is changing our world. The predominant activity of IBM Czech Republic is the sale of IBM's broad spectrum of IT technologies, from servers and storage systems to software and IT services, including consultancy services. The main objectives of IBM include the provision of comprehensive services of systems integration and the promotion of the benefits of e-commerce into everyday life, including the provision of smart solutions leading to sustainable development. An integral part of IBM’s strategy is corporate social responsibility programs, through which IBM contributes to addressing the environmental and social needs of society. In view of its turnover, the breadth of its offer, and the number of employees, IBM Czech Republic holds the same position in the country as it has reached around the world.
Cooperation with FNUSA-ICRCCooperation between IBM, FNUSA-ICRC, and the Mayo Clinic will be developed mainly in the fields of nanotechnologies, information system development, and information-based medicine.
Linet, Ltd., was founded in 1990 and is a leading world manufacturer of beds and interior furnishings for acute and social care. Linet is the largest producer of acute beds in Europe and ranks among the top five largest companies in its field in the world. It is also the fastest growing company of this branch in Europe. The main products of the company are beds for hospitals and nursing homes, mattresses, furniture, and other medical equipment. The products are manufactured in the company’s own manufacturing plants and distributed to more than 95 countries through its own distribution network.
Cooperation with FNUSA-ICRCThe expected results of cooperation between Linet, Ltd., and FNUSA-ICRC are the installation and a pilot project of a bed system for intensive inpatient care, the implementation of the "patient and bed management" system, and the development and clinical testing of new products.
- M & I
The Czech company M & I, Ltd., has been active on the market of medical devices since 1990, specializing in systems used in neurology, cardiology, psychiatry, and research laboratories for sleep disorders. M & I develops, manufactures, and supplies a special bio-amplifier with digital output, including software for recording and analysis. The system is marketed in the Czech Republic under the BrainScope trade mark. It is a system for recording, archiving, and analyzing EEG/EP, polysomnography, and biological signals in general.
Cooperation with FNUSA-ICRCWithin FNUSA-ICRC, cooperation will be focused on the development of new devices for biological signal processing and research and development in the field of sleep disorders.
Medesa, Ltd., is a company founded in 1996 and fully owned by natural persons from the Czech Republic. At present, the company ranks among the major suppliers of complex equipment for medium-sized and smaller clinical laboratories in the Czech Republic. The company mainly emphasizes technical and technological quality and maximum user and service security. The company has been a holder of the ISO 9001:2000 certificate since 2003.
Cooperation with FNUSA-ICRCThe main area of cooperation will be the development of new medical devices for in vitro diagnosis, and laboratory equipment, reagents, and consumables for science and research in health care.
- Select Research
Select Research is one of the leading companies in the UK, with more than fifteen years of experience in the development and use of 3D scanners in medicine. The company created an information brochure designed to assess patients for health care based on volume and regional distribution. The company also pioneered the use of 3D Body Scanning for measurement and assessment of obesity-related health risks. The activities of Select Research are focused on qualitative research in a wide range of industries in both the public and private sectors. In 2004, the company developed the Body Volume Index as a potential way to measure obesity in the 21st century. Every year the company invests significant funds into research and development.
Cooperation with FNUSA-ICRCSince 2007, Select Research has collaborated on the development of the Body Volume Index (BVI) with the Mayo Clinic, where there are now two BVI scanners for the purpose of further development. The company (together with the UK government) provided the Mayo Clinic with funds to develop the BVI scanner and for other studies focusing particularly on the risk of cardiovascular diseases. These studies were carried out in cooperation with FNUSA-ICRC. Cooperation with the Mayo Clinic thus forms part of an extensive study of the BVI, in which many other medical facilities are also involved, with the goal of using the BVI as a new anthropometric measuring device in health care in the 21st century. Select Research considers FNUSA-ICRC as providing an opportunity for joint research and development of the BVI.
From mid-May FNUSA-ICRC will be led by Slovenian neurologist Gorazd Stokin More
Invitation: Mendel Lecture "Genome stability and the control of recombination" More